Facial Skin Changes Produced by Treatment with Autologous Platelet Concentrate

Abstract

Background: The tireless search for therapeutic options that alleviate the signs of skin aging is a challenge for the aesthetic practitioner. Objective: To evaluate the efficacy and safety of autologous platelet concentrate (APC) in the treatment of facial cutaneous aging (FCA). Method: Between March 1, 2017 and March 31, 2021 at the “Hermanos Ameijeiras” hospital, a randomized, singlecenter, double-blind and controlled clinical trial was carried out in 164 patients with FCA. A group treated with APC was compared to another treated with fresh autologous plasma (FAP). The treatment was applied monthly for 1 year. Results: Three months after the end of the treatment, there were significant differences between the patients treated with APC compared to those treated with FAP in terms of improvement in the texture, tone, elasticity, hydration, pores, homogeneity of the skin, the global aesthetic improvement scale (GAIS) and degree of satisfaction (p <0.001). All adverse events were of mild intensity, did not imply changes before the intervention and were completely resolved. Conclusions: The autologous platelet concentrate proved to be effective and safe in reducing the signs of skin aging, associated with a high degree of patient satisfaction.